Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Targacept Inc

+ Add to Watchlist

TRGT:US

2.7500 USD 0.00000.00%

As of 20:10:00 ET on 05/29/2015.

Snapshot for Targacept Inc (TRGT)

Open: 2.7595 Day's Range: 2.7401 - 2.7600 Volume: 93,201
Previous Close: 2.7500 52wk Range: 2.1500 - 4.6800 1-Yr Rtn: -26.67%

Stock Chart for TRGT

No chart data available.
  • TRGT:US 2.7500
  • 1D
  • 1M
  • 1Y
2.7500
Interactive TRGT Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TRGT

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.7000
Est. EPS (USD) (12/2015) -
Est. PEG Ratio -
Market Cap (M USD) 93.15
Shares Outstanding (M) 33.87
30 Day Average Volume 76,538
Price/Book (mrq) 0.9023
Price/Sale (ttm) 374.7284
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TRGT

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for TRGT

Targacept Inc. is a a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting neuronal nicotinic acetylcholine receptors.

Stephen Anthony Hill "Steve"President/CEOPatrick C RockSenior VP/Secy/General Counsel
Mauri K HodgesVP:Finance/CFO/TreasurerScott N CullisonVP:Business Development
More Company Profile & Key Executives for TRGT

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil